In 2013, Google announced it would attempt to understand and ultimately slow aging through a company called Calico, a moonshot effort that would ultimately absorb at least $3.5 billion in funding, spawn rampant speculation, and generate dozens of academic papers but deliver few tangible results — until Monday.
The first data have now emerged from a drug Calico developed. It failed.
The pill, known as fosigotifator, was not designed to slow aging itself. The Food and Drug Administration does not consider aging a disease and it would be incredibly costly and time-consuming to even attempt to prove that a drug extends lifespan — so most “longevity” companies have started by tackling specific age-related diseases.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.